TEAM
Experienced entrepreneurs with extensive biotech and immunotherapy experience.
>25 years of Pharma/Biotech R&D experience in vaccine tech development. Co-founder & CSO of Mucosis, Inventor of bacterial particle technology.
Biotechnologist, PhD
Kees Leenhouts
COO & CTO
>25 years of Pharma/Biotech R&D experience in vaccine tech development. Co-founder & CSO of Mucosis, Inventor of bacterial particle technology. Biotechnologist, PhD.
Poul Sørensen
CSO
>25 years of Pharma/Biotech R&D experience in immunotherapy. Senior Management at ALK, Stallergenes, LEO Pharma, Micromet, Pharmacia. Professor of Biomedicine, PhD.
Emil Pot
CEO
>20 years of experience in technology transfer and biotech start-up companies. Co-founder of ActoGenix, IP expert at NLO & BD Oncode, LL.M. EU Patent Attorney.
Kim Simonsen
CMO
>30+ yrs senior management experience in medical and regulatory affairs including Novo Nordisk, Novartis, ALK, Ablynx, Anergis, Galapagos. Medical Doctor.
SCIENTIFIC ADVISORY BOARD
Federico Grego
CFO
>20 years of senior management experience in Allergy sector. Executive VP LETI Pharma, CEO Spire Bioventures, GM at nLife Therapeutics & CBO Cytovation AS. Economist, MBA.
Allero has put together a Scientific Advisory Board established with world leading key opinion leaders that has supported and challenged the founding team since the very beginning of the project. The SAB includes leading experts in Immunology and immune mediated disorders with particular focus on Celiac Disease and Allergy, and Clinical Development.